安科生物(300009)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300009 安科生物

已收盘 12-20 15:00:00

{"stockData":{"symbol":"300009","market":"SZ","secType":"STK","nameCN":"安科生物","latestPrice":9.01,"timestamp":1734678189000,"preClose":8.98,"halted":0,"volume":10835433,"delay":0,"floatShares":1222000000,"shares":1673000000,"eps":0.4679,"marketStatus":"已收盘","marketStatusCode":5,"change":0.03,"latestTime":"12-20 15:00:00","open":8.97,"high":9.09,"low":8.95,"amount":97821900,"amplitude":0.0156,"askPrice":9.01,"askSize":21,"bidPrice":9,"bidSize":735,"shortable":0,"etf":0,"ttmEps":0.4679,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":8.98,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":9.88,"lowLimit":8.08,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1672553658,"pbRate":3.81,"roa":"--","roe":"15.47%","epsLYR":0.51,"committee":0.335509,"marketValue":15070000000,"floatMarketCap":11008000000,"peRate":19.256251,"changeRate":0.0033,"turnoverRate":0.0089,"status":0},"requestUrl":"/m/hq/s/300009","defaultTab":"news","newsList":[{"id":"2492123349","title":"安科生物2024年前三季度利润分配方案：拟10派1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492123349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492123349?lang=zh_cn&edition=full","pubTime":"2024-12-19 19:00","pubTimestamp":1734606051,"startTime":"0","endTime":"0","summary":"安科生物公告，公司董事会拟定2024年前三季度利润分配方案：拟向全体股东按每10股派发现金股利1元（含税），共计派发现金股利1.67亿元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900032036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300009","BK0070","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2492140663","title":"安科生物：拟向全体股东每10股派发现金股利1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492140663","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492140663?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:37","pubTimestamp":1734604630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0070","BK0042","BK0239","BK0060","300009"],"gpt_icon":0},{"id":"2492140696","title":"安科生物(300009.SZ)前三季度利润分配拟10股派1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492140696","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492140696?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:34","pubTimestamp":1734604444,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)披露2024年前三季度利润分配方案，公司拟向全体股东按每10股派发现金股利1元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300009","BK0239","BK0042","BK0070"],"gpt_icon":0},{"id":"2488416859","title":"安科生物：公司高管对于公司的经营发展充满了信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2488416859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488416859?lang=zh_cn&edition=full","pubTime":"2024-12-04 18:00","pubTimestamp":1733306436,"startTime":"0","endTime":"0","summary":"公司多次召开关于市值管理的会议，制定了管理方案，对内将从生产、研发、销售等多方面提高公司的核心价值，提升核心竞争力；对外积极与行业研究员、基金经理沟通交流，推广公司的价值。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400032734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300009","BK0060","BK0239","BK0070","BK0042"],"gpt_icon":0},{"id":"2488761337","title":"安科生物（300009）601.25万股限售股将于12月2日解禁，占总股本0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488761337","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488761337?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:03","pubTimestamp":1733097808,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，安科生物于12月2日将有601.25万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.36%。本次解禁后，公司还有4.55亿股限售股份，占总股本27.12%。安科生物主营业务：一家以生物医药产业为主的具有自主创新能力的国家级高新技术企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200001075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300009","BK0060","BK0042"],"gpt_icon":0},{"id":"2486770271","title":"安科生物最新公告：人生长激素注射液新增适应症申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486770271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486770271?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:00","pubTimestamp":1732525240,"startTime":"0","endTime":"0","summary":"安科生物公告，公司收到国家药品监督管理局行政许可文书《受理通知书》，人生长激素注射液新增小于胎龄儿（SGA）适应症的补充申请事项获得受理。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500021497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300009","BK0239","BK0060","BK0070"],"gpt_icon":0},{"id":"2486706247","title":"安科生物(300009.SZ)：人生长激素注射液新增适应症申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486706247","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486706247?lang=zh_cn&edition=full","pubTime":"2024-11-25 16:58","pubTimestamp":1732525132,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)公告，公司收到国家药品监督管理局行政许可文书《受理通知书》，公司人生长激素注射液新增小于胎龄儿适应症的补充申请事项获得受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300009","BK0070","BK0042","BK0239"],"gpt_icon":0},{"id":"2484163371","title":"安科生物(300009.SZ)实控人宋礼华、宋礼名及董事赵辉拟合计减持0.97%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2484163371","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484163371?lang=zh_cn&edition=full","pubTime":"2024-11-20 21:19","pubTimestamp":1732108780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)公告，公司收到控股股东、实际控制人、董事兼高级管理人员宋礼华先生，控股股东、实际控制人、董事宋礼名先生，董事、高级管理人员赵辉女士关于减持公司股份计划的告知函，上述股东合计拟减持公司股份1620万股，占公司总股本的0.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300009","BK0239","BK0042","BK0070"],"gpt_icon":0},{"id":"2484911502","title":"安科生物最新公告：控股股东、实控人及部分董事、高管拟减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2484911502","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484911502?lang=zh_cn&edition=full","pubTime":"2024-11-20 21:10","pubTimestamp":1732108231,"startTime":"0","endTime":"0","summary":"安科生物公告，公司实际控制人、控股股东、董事兼高级管理人员宋礼华，控股股东、实际控制人、董事宋礼名，以及董事兼高级管理人员赵辉计划减持公司股份。宋礼华计划减持1200万股，占公司总股本0.72%；宋礼名计划减持400万股，占公司总股本0.24%；赵辉计划减持20万股，占公司总股本0.01%。减持方式包括集中竞价、大宗交易等，减持期间为自公告披露之日起十五个交易日后的三个月内。本次减持计划实施存在不确定性，股东将根据市场情况、公司股价情况等决定是否实施本次股份减持计划。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000037717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300009","BK0239","BK0042","BK0070"],"gpt_icon":0},{"id":"2484169589","title":"11月20日安科生物现1笔大宗交易 机构净买入202.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484169589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484169589?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:47","pubTimestamp":1732092422,"startTime":"0","endTime":"0","summary":"证券之星消息，11月20日安科生物发生大宗交易，交易数据如下：大宗交易成交价格9.4元，成交21.5万股，成交金额202.1万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交2150.0手。该股近期无解禁股上市。截至2024年11月20日收盘，安科生物(300009)报收于9.4元，上涨1.84%，换手率1.8%，成交量21.87万手，成交额2.04亿元。该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为10.52。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000028121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0042","BK0239","BK0060","300009"],"gpt_icon":0},{"id":"2478111652","title":"安科生物（300009）10月25日主力资金净卖出3074.52万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478111652","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478111652?lang=zh_cn&edition=full","pubTime":"2024-10-28 09:22","pubTimestamp":1730078552,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月25日收盘，安科生物报收于9.24元，下跌1.28%，换手率3.28%，成交量39.88万手，成交额3.65亿元。近5日资金流向一览见下表：安科生物融资融券信息显示，融资方面，当日融资买入2586.4万元，融资偿还2896.08万元，融资净偿还309.69万元。安科生物主营业务：一家以生物医药产业为主的具有自主创新能力的国家级高新技术企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800002233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0042","BK0070","BK0239","300009"],"gpt_icon":0},{"id":"2477361506","title":"安科生物(300009.SZ)发布前三季度业绩，净利润5.9亿元，同比下降9.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477361506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477361506?lang=zh_cn&edition=full","pubTime":"2024-10-24 21:16","pubTimestamp":1729775786,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)发布2024年三季度报告，前三季度，公司实现营业收入19.21亿元，同比下降4.95%。归属于上市公司股东的净利润5.9亿元，同比下降9.89%。归属于上市公司股东的扣除非经常性损益的净利润5.55亿元，同比下降11.93%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300009"],"gpt_icon":0},{"id":"2476431121","title":"安科生物最新公告：子公司依替巴肽原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2476431121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476431121?lang=zh_cn&edition=full","pubTime":"2024-10-17 18:51","pubTimestamp":1729162273,"startTime":"0","endTime":"0","summary":"安科生物公告，旗下全资子公司苏豪逸明的依替巴肽原料药获得国家药品监督管理局批准上市。这标志着该产品具备国内市场准入资格，有助于丰富产品管线，拓展业务领域，提高公司核心竞争力。依替巴肽通过抑制血小板聚集，被用于治疗急性冠状动脉综合征患者。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101700028185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300009","BK0239","BK0042","BK0070"],"gpt_icon":0},{"id":"2476507143","title":"安科生物(300009.SZ)子公司依替巴肽原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2476507143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476507143?lang=zh_cn&edition=full","pubTime":"2024-10-17 18:50","pubTimestamp":1729162207,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)发布公告，近日，安徽安科生物工程(集团)股份有限公司全资子公司上海苏豪逸明制药有限公司(简称“苏豪逸明”)收到国家药品监督管理局签发的依替巴肽原料药《化学原料药上市申请批准通知书》，并在国家药品监督管理局药品审评中心官方网站公示，与制剂共同审批结果为A。本次依替巴肽原料药的批准上市，标志着该品已具备国内市场准入资格，有利于丰富子公司产品管线，进一步拓展子公司业务领域，提高核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300009","BK0239","BK0042","BK0060","BK0070"],"gpt_icon":0},{"id":"2473446142","title":"10月8日安科生物涨9.16%，天弘国证生物医药ETF发起式联接A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2473446142","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473446142?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:34","pubTimestamp":1728380092,"startTime":"0","endTime":"0","summary":"根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为天弘国证生物医药ETF发起式联接A。天弘国证生物医药ETF发起式联接A目前规模为1.36亿元，最新净值0.4471，较上一交易日上涨11.94%，近一年下跌13.52%。天弘国证生物医药ETF发起式联接A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800026312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300009","BK0060","BK0042","512290"],"gpt_icon":0},{"id":"2473844614","title":"安科生物涨9.16%，国金证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2473844614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473844614?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:34","pubTimestamp":1728380088,"startTime":"0","endTime":"0","summary":"今日安科生物涨9.16%，收盘报10.73元。2024年8月28日，国金证券研究员袁维发布了对安科生物的研报《业绩整体稳定，研发创新持续深入》，该研报对安科生物给出“买入”评级。维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为59.66%。安科生物个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800026307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300009"],"gpt_icon":0},{"id":"2471800440","title":"安科生物(300009.SZ)：安徽安科余良卿药业暂停生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2471800440","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471800440?lang=zh_cn&edition=full","pubTime":"2024-09-30 21:09","pubTimestamp":1727701757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)公告，公司接到控股子公司安徽安科余良卿药业有限公司(简称“余良卿公司”)通知，安徽省药品监督管理局近期对余良卿公司进行了GMP符合性检查，因余良卿公司存在部分厂房设施、设备陈旧等原因，达不到现行GMP管理的相关要求，余良卿公司暂停生产。本次暂停生产，不存在要求余良卿公司召回已销售的相关产品的情形，也不影响库存产品继续销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1189314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300009","BK0239","BK0042","BK0070","BK0060"],"gpt_icon":0},{"id":"2471800999","title":"安科生物(300009.SZ)：人干扰素α2b滴眼液生产注册补充申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2471800999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471800999?lang=zh_cn&edition=full","pubTime":"2024-09-30 21:06","pubTimestamp":1727701617,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)公告，公司收到国家药品监督管理局行政许可文书《受理通知书》，公司人干扰素α2b滴眼液生产注册补充申请已获受理。本次补充申请的产品为公司已上市产品“人干扰素α2b滴眼液”的升级优化，系单剂量装人干扰素α2b滴眼液。目前，公司已新建一条人干扰素α2b滴眼液吹灌封(吹塑blow-灌装fill-密封seal，简称BFS)商业化生产线，用于生产单剂量装滴眼液制剂。单剂量装人干扰素α2b滴眼液不含抑菌剂，使用更安全，同时根据双眼1次或1天用量确定装量，具有经济性、使用和携带方便的特点，能够避免多剂量产品在多次使用过程中因患者操作不当可能带来的药液污染风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1189312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300009","BK0070","BK0042","BK0060","BK0239"],"gpt_icon":0},{"id":"2471802076","title":"安科生物最新公告：控股子公司暂停生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2471802076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471802076?lang=zh_cn&edition=full","pubTime":"2024-09-30 20:39","pubTimestamp":1727699992,"startTime":"0","endTime":"0","summary":"安科生物公告，公司接到控股子公司安徽安科余良卿药业有限公司通知，安徽省药品监督管理局近期对余良卿公司进行了GMP符合性检查，因余良卿公司存在部分厂房设施、设备陈旧等原因，达不到现行GMP管理的相关要求，余良卿公司暂停生产。余良卿公司为公司持股72.54%的控股子公司，2023年度余良卿公司实现净利润为5750万元，占公司2023年度归属于上市公司股东净利润的6.79%。此次停产整改，预计不会对公司整体经营业绩产生重大影响，同日公告，公司人干扰素α2b滴眼液生产注册补充申请已获受理。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000040733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0070","BK0239","BK0042","300009"],"gpt_icon":0},{"id":"2468303402","title":"安科生物(300009.SZ)部分产品获第一类医疗器械备案凭证","url":"https://stock-news.laohu8.com/highlight/detail?id=2468303402","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468303402?lang=zh_cn&edition=full","pubTime":"2024-09-18 17:37","pubTimestamp":1726652239,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)公告，公司于近日取得合肥市市场监督管理局核发的《第一类医疗器械备案编号告知书》，产品名称分别为钙荧光白染色液(CFW)及免疫显色试剂，预期用途分别为人体组织样本真菌细胞壁染色及脱落细胞染色。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184137.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","BK0060","BK0042","BK0070","BK0239","BK1222","BK1574","BK1583","BK1100","300009","09996","159883"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-10-30","address":"安徽省合肥市蜀山区长江西路669号高新区海关路K-1","stockEarnings":[{"period":"1week","weight":-0.0066},{"period":"1month","weight":-0.0415},{"period":"3month","weight":0.1871},{"period":"6month","weight":0.0204},{"period":"1year","weight":-0.0828},{"period":"ytd","weight":-0.0953}],"companyName":"安徽安科生物工程(集团)股份有限公司","boardCode":"AI0027","perCapita":"18342股","boardName":"医药制造业","registeredCapital":"167255万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":"　　安徽安科生物工程(集团)股份有限公司是一家医药高新技术企业,公司主营业务为基因工程药品、生物检测试剂的研发、生产、销售,主要产品有:注射用重组人干扰素α2b冻干粉针、重组人干扰素α2b注射液、重组人干扰素α2b乳膏、重组人干扰素α2b滴眼液、重组人干扰素α2b栓剂、注射用重组人生长激素、抗精子抗体检测试剂盒等。公司主导产品重组人干扰素α2b\"安达芬\"系列制剂、重组人生长激素\"安苏萌\"、抗精子抗体检测(MAR法)试剂盒\"安思宝\"均由安科自主研发,畅销全国并出口十多个国家和地区.其中\"安达芬\"是我国第一个国产化干扰素α2b产品,国家\"863\"计划成果\"安思宝\"是国际上第一个商品化的MAR法抗精子抗体检测试剂。","serverTime":1734724874969,"listedPrice":17,"stockholders":"66605人(较上一季度减少1.49%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安科生物(300009)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安科生物(300009)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安科生物,300009,安科生物股票,安科生物股票老虎,安科生物股票老虎国际,安科生物行情,安科生物股票行情,安科生物股价,安科生物股市,安科生物股票价格,安科生物股票交易,安科生物股票购买,安科生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安科生物(300009)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安科生物(300009)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}